• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

与阿尔茨海默病中tau病理开始年龄以及从tau开始到痴呆的时间相关的因素。

Factors associated with age at tau pathology onset and time from tau onset to dementia in Alzheimer's disease.

作者信息

Heston Margo B, Teague Jordan P, Cody Karly A, Deming Yuetiva, Ruiz de Chavez Elena, Morse Jacob, Chin Nathaniel A, Engelman Corinne D, Chappell Richard J, Langhough Rebecca E, Gleason Carey E, Clark Lindsay R, Zuelsdorff Megan L, Betthauser Tobey J

机构信息

Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.

Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.

出版信息

Alzheimers Dement. 2025 Aug;21(8):e70551. doi: 10.1002/alz.70551.

DOI:10.1002/alz.70551
PMID:40859634
Abstract

INTRODUCTION

Elevated tau (T+) is temporally proximal to dementia onset but less is known about factors influencing T+ onset age and time to dementia after T+ in Alzheimer's disease (AD). We used sampled iterative local approximation (SILA) estimated T+ onset age (ETOA) to investigate factors associated with T+ age and time from T+ to dementia onset in the Alzheimer's Disease Neuroimaging Initiative.

METHODS

Using SILA-estimated amyloid positivity and T+ onset ages derived from F-Flortaucipir, F-Florbetapir, and F-Florbetaben positron emission tomography and Cox proportional hazards and accelerated failure time models, we analyzed apolipoprotein E (APOE), sex, amyloid burden, age, educational attainment, and literacy associations with ETOA and time from T+ to dementia.

RESULTS

Higher amyloid, APOE-ε4, lower education, and lower literacy associated with younger ETOA. Older ETOA and higher amyloid associated with shorter time from T+ to dementia.

DISCUSSION

This work highlights the prognostic value of ETOA and the need to better characterize factors contributing to ETOA and dementia onset in AD.

HIGHLIGHTS

We applied sampled iterative local approximation (SILA) to Alzheimer's Disease Neuroimaging Initiative F-Flortaucipir data, to estimate individuals' age of tau pathology onset (T+) and time from T+ onset to dementia. Higher amyloid, apolipoprotein E ε4, lower education, and lower literacy associated with younger estimated T+ onset age. Older T+ onset age and higher amyloid associated with shorter time from T+ to dementia. Only one individual was observed to remain dementia free 14 years after T+ onset. This work highlights the prognostic value of T+ onset age and the need to better characterize factors contributing to T+ onset age and dementia onset in Alzheimer's disease.

摘要

引言

tau升高(T+)在时间上与痴呆症发病临近,但对于阿尔茨海默病(AD)中影响T+发病年龄以及T+后至痴呆症发病时间的因素,我们了解得较少。我们使用抽样迭代局部近似法(SILA)估计T+发病年龄(ETOA),以研究阿尔茨海默病神经影像倡议(ADNI)中与T+年龄以及从T+到痴呆症发病时间相关的因素。

方法

利用从氟代tau蛋白显像剂F-Flortaucipir、氟代贝他匹F-Florbetapir和氟代贝他班F-Florbetaben正电子发射断层扫描得出的SILA估计的淀粉样蛋白阳性结果和T+发病年龄,以及Cox比例风险模型和加速失效时间模型,我们分析了载脂蛋白E(APOE)、性别、淀粉样蛋白负荷、年龄、受教育程度和读写能力与ETOA以及从T+到痴呆症的时间之间的关联。

结果

较高的淀粉样蛋白、APOE-ε4、较低的教育程度和较低的读写能力与较年轻的ETOA相关。较老的ETOA和较高的淀粉样蛋白与从T+到痴呆症的较短时间相关。

讨论

这项工作突出了ETOA的预后价值,以及更好地描述导致AD中ETOA和痴呆症发病的因素的必要性。

要点

我们将抽样迭代局部近似法(SILA)应用于阿尔茨海默病神经影像倡议(ADNI)的氟代tau蛋白显像剂F-Flortaucipir数据,以估计个体的tau病理发病年龄(T+)以及从T+发病到痴呆症的时间。较高的淀粉样蛋白、载脂蛋白E ε4、较低的教育程度和较低的读写能力与较年轻的估计T+发病年龄相关。较老的T+发病年龄和较高的淀粉样蛋白与从T+到痴呆症的较短时间相关。仅观察到一名个体在T+发病14年后仍未患痴呆症。这项工作突出了T+发病年龄的预后价值,以及更好地描述导致阿尔茨海默病中T+发病年龄和痴呆症发病的因素的必要性。

相似文献

1
Factors associated with age at tau pathology onset and time from tau onset to dementia in Alzheimer's disease.与阿尔茨海默病中tau病理开始年龄以及从tau开始到痴呆的时间相关的因素。
Alzheimers Dement. 2025 Aug;21(8):e70551. doi: 10.1002/alz.70551.
2
Factors associated with age at tau pathology onset and time from tau onset to dementia.与tau病理开始年龄以及从tau开始到痴呆的时间相关的因素。
medRxiv. 2025 Mar 13:2025.03.11.25323773. doi: 10.1101/2025.03.11.25323773.
3
Temporal sequence of amyloid and tau PET positivity: -ε4 and sex effects, and implications for Alzheimer's disease progression.淀粉样蛋白和tau蛋白PET阳性的时间序列:-ε4和性别影响以及对阿尔茨海默病进展的意义。
medRxiv. 2025 Jul 28:2025.07.27.25332202. doi: 10.1101/2025.07.27.25332202.
4
18F PET with florbetapir for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).使用氟代硼吡咯进行18F正电子发射断层显像以早期诊断轻度认知障碍(MCI)患者的阿尔茨海默病性痴呆及其他痴呆。
Cochrane Database Syst Rev. 2017 Nov 22;11(11):CD012216. doi: 10.1002/14651858.CD012216.pub2.
5
18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).使用氟代甲磺酸去甲肾上腺素的18F正电子发射断层显像用于轻度认知障碍(MCI)患者中阿尔茨海默病性痴呆及其他痴呆的早期诊断。
Cochrane Database Syst Rev. 2017 Nov 22;11(11):CD012884. doi: 10.1002/14651858.CD012884.
6
Timeline to symptomatic Alzheimer's disease in people with Down syndrome as assessed by amyloid-PET and tau-PET: a longitudinal cohort study.淀粉样蛋白 PET 和 tau-PET 评估唐氏综合征患者症状性阿尔茨海默病的时间轴:一项纵向队列研究。
Lancet Neurol. 2024 Dec;23(12):1214-1224. doi: 10.1016/S1474-4422(24)00426-5.
7
Longitudinal Evolution of Financial Capacity and Cerebral Tau and Amyloid Burden in Older Adults with Normal Cognition or Mild Cognitive Impairment.认知正常或轻度认知障碍老年人的财务能力和大脑 Tau 与淀粉样蛋白负担的纵向演变。
J Prev Alzheimers Dis. 2024;11(4):966-974. doi: 10.14283/jpad.2023.121.
8
Impact of diabetes on the progression of Alzheimer's disease via trajectories of amyloid-tau-neurodegeneration (ATN) biomarkers.糖尿病通过淀粉样蛋白- tau-神经变性(ATN)生物标志物轨迹对阿尔茨海默病进展的影响。
J Nutr Health Aging. 2025 Feb;29(2):100444. doi: 10.1016/j.jnha.2024.100444. Epub 2024 Dec 10.
9
Comparison of tau spread in people with Down syndrome versus autosomal-dominant Alzheimer's disease: a cross-sectional study.唐氏综合征与常染色体显性阿尔茨海默病患者 Tau 蛋白扩散的比较:一项横断面研究。
Lancet Neurol. 2024 May;23(5):500-510. doi: 10.1016/S1474-4422(24)00084-X.
10
¹⁸F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).¹⁸F - 氟代脱氧葡萄糖正电子发射断层显像(¹⁸F - FDG PET)用于轻度认知障碍(MCI)患者中阿尔茨海默病性痴呆及其他痴呆的早期诊断。
Cochrane Database Syst Rev. 2015 Jan 28;1(1):CD010632. doi: 10.1002/14651858.CD010632.pub2.

本文引用的文献

1
Alzheimer Disease as a Clinical-Biological Construct-An International Working Group Recommendation.作为一种临床生物学概念的阿尔茨海默病——国际工作组建议
JAMA Neurol. 2024 Dec 1;81(12):1304-1311. doi: 10.1001/jamaneurol.2024.3770.
2
Tau PET positivity predicts clinically relevant cognitive decline driven by Alzheimer's disease compared to comorbid cases; proof of concept in the ADNI study.与合并症病例相比,Tau正电子发射断层扫描(PET)阳性可预测由阿尔茨海默病驱动的临床相关认知衰退;阿尔茨海默病神经成像计划(ADNI)研究中的概念验证。
Mol Psychiatry. 2025 Feb;30(2):587-599. doi: 10.1038/s41380-024-02672-9. Epub 2024 Aug 23.
3
Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission.
《痴呆症的预防、干预与照护:柳叶刀常设委员会2024年报告》
Lancet. 2024 Aug 10;404(10452):572-628. doi: 10.1016/S0140-6736(24)01296-0. Epub 2024 Jul 31.
4
Sex and gender differences in cognitive resilience to aging and Alzheimer's disease.衰老和阿尔茨海默病认知弹性的性别差异。
Alzheimers Dement. 2024 Aug;20(8):5695-5719. doi: 10.1002/alz.13844. Epub 2024 Jul 5.
5
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup.修订的阿尔茨海默病诊断和分期标准:阿尔茨海默病协会工作组。
Alzheimers Dement. 2024 Aug;20(8):5143-5169. doi: 10.1002/alz.13859. Epub 2024 Jun 27.
6
Association between Fine Particulate Matter Exposure and Cerebrospinal Fluid Biomarkers of Alzheimer's Disease among a Cognitively Healthy Population-Based Cohort.基于认知健康人群队列的细颗粒物暴露与阿尔茨海默病脑脊液生物标志物的相关性研究。
Environ Health Perspect. 2024 Apr;132(4):47001. doi: 10.1289/EHP13503. Epub 2024 Apr 3.
7
Disease staging of Alzheimer's disease using a CSF-based biomarker model.采用基于脑脊液生物标志物模型对阿尔茨海默病进行疾病分期。
Nat Aging. 2024 May;4(5):694-708. doi: 10.1038/s43587-024-00599-y. Epub 2024 Mar 21.
8
Individuals with Alzheimer's disease and low tau burden: Characteristics and implications.阿尔茨海默病患者和低 tau 负担者:特征和意义。
Alzheimers Dement. 2024 Mar;20(3):2113-2127. doi: 10.1002/alz.13609. Epub 2024 Jan 19.
9
The Alzheimer's Disease Neuroimaging Initiative in the era of Alzheimer's disease treatment: A review of ADNI studies from 2021 to 2022.阿尔茨海默病神经影像学倡议在阿尔茨海默病治疗时代:对 2021 年至 2022 年 ADNI 研究的回顾。
Alzheimers Dement. 2024 Jan;20(1):652-694. doi: 10.1002/alz.13449. Epub 2023 Sep 12.
10
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.多奈哌齐治疗早期症状性阿尔茨海默病的随机临床试验。
JAMA. 2023 Aug 8;330(6):512-527. doi: 10.1001/jama.2023.13239.